A reversible topical male contraceptive may be close r to reality, based of the results of a randomized trial.
Reversible topical male contraception may be closer to reality, based on results of a randomized trial of a combination gel released at The Endocrine Society's 94th Annual Meeting in Houston. Daily use of the testosterone/ progestin transdermal product suppressed sperm concentration to ≤1 million/mL in nearly 90% of men with minimal adverse effects, compared with only 23% of those on transdermal testosterone alone.
Funded by the National Institutes of Health and The Population Council, the double-blind study of 99 healthy male volunteers was performed at Harbor-UCLA Medical Centers and Los Angeles Biomedical Research Institute and the University of Washington. Subjects were randomized to daily application of one of three transdermal gels: 10 g testosterone + placebo gel (T alone); 10 g testosterone + 8 mg Nestorone (T+NES 10 mg); and 10 g testosterone + 12 mg Nestorone (T+NES 12 mg). Of the 56 subjects who adhered to the protocol and completed at least 20 weeks' treatment, significantly more men using T+NES 8 mg (78%; P<.001) and T+NES 12 mg (69%; P<.008) became azoospermic than those using testosterone alone (23%). As sperm concentration dropped, so did sperm motility and normal morphology.
Median total and free testosterone concentrations remained within the adult male range irrespective of treatment group. All subjects recovered to a sperm concentration =15 million/mL during the recovery period. Unlike other progestins studied as male contraceptives, Nestorone has no androgenic activity. This is the first study of topical testosterone and Nestorone for male contraception and the investigators believe the findings warrant further investigation of the compound.
Adverse maternal outcomes after uterine conservation in placenta accreta spectrum
May 9th 2024A review of 5 studies reveals a significant 1 in 4 incidence of adverse maternal outcomes following uterine conservation in patients with placenta accreta spectrum, underlining the importance of expert multidisciplinary care.
Read More
Barriers in seeking pelvic floor disorder treatment among ethnic minorities
May 8th 2024A recent shed light on how ethnic minority groups perceive pelvic floor disorders, highlighting barriers to treatment seeking and the importance of raising awareness about available treatment options.
Read More
Variations found in testosterone therapy for women with HSDD
May 7th 2024Dive into the intricate landscape of testosterone therapy prescriptions among women with hypoactive sexual desire disorder, revealing diverse patterns in duration, administration routes, and estrogen co-administration.
Read More